New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
08:41 EDTMDVNMedivation weakness a buying opportunity, says UBS
UBS said Medivation weakness from the PREVAIL presentation is a buying opportunity and said its Q4 urology survey indicates topline PREVAIL data will drive robust utilization. Shares are Buy rated with a $93 price target.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
08:03 EDTMDVNMedivation lowered expectations skews risk/reward to upside, says UBS
UBS noted Medivation shares have been weak since ASCO but believes the risk reward has been skewed to the upside. The firm said its thesis is different from consensus as they believe the company's pipeline advancement this year could drive multiple expansion if Xtandi sales can at least remain flat. UBS reiterated its Buy rating and $142 price target on Medivation shares.
June 17, 2015
07:08 EDTMDVNMedivation, Astellas Pharma announce enrollment of first patients in TRUMPET
Subscribe for More Information
07:07 EDTMDVNMedivation and Astellas Pharma enroll first patients in prostate cancer registry
Astellas (ALPMY) and Medivation (MDVN) have enrolled the first patients in TRUMPET - Treatment Registry for Outcomes in CRPC Patients -, a prospective observational patient registry designed to better understand the unique needs and treatment patterns for patients with castration-resistant prostate cancer. The registry will enroll and evaluate 2,000 patients diagnosed with CRPC from urology and oncology sites across the U.S. TRUMPET is currently enrolling eligible patients and their caregivers; the study will be completed in 2020.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use